<DOC>
	<DOC>NCT02573350</DOC>
	<brief_summary>A phase 2, multicenter, uncontrolled, open-label trial in patients with MDR-TB. Only patients who completed Trial 204 were eligible. The trial was performed globally at 14 sites qualified to treat MDR-TB. All 434 patients who completed Trial 204 were eligible for this trial if there was still potential clinical benefit to them and all inclusion criteria and no exclusion criteria were met.</brief_summary>
	<brief_title>A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
	<criteria>Provide written, informed consent prior to all trialrelated procedures Male or female patients aged between 18 and 64 years, inclusive, at the time of enrollment into the 24207204 trial. Patients who were 64 years at the time of 204 enrollment and who are now 65 years, are eligible for this trial. Patients who have completed trial 24207204 Patients judged by the investigator to have the potential for clinical benefit from OPC67683 exposure Able to produce sputum for mycobacterial culture or able to obtain sputum produced through induction Female patients of childbearing potential must have a negative urine pregnancy test and agree to use a highly effective method of birth control throughout the participation in the trial and for 22 weeks after last dose. Male patients must agree to use an adequate method of contraception (double barrier) throughout the participation in the trial and for 30weeks after last dose. Greater than 30 days has elapsed from the patient's date of completion in the 24207204 trial or greater than 30 days has elapsed since the patient's trial investigator's site was initiated in this trial, whichever is later.a A history of allergy to any nitroimidazoles or nitroimidazole derivates at any time. Use of the medications in Section 5.4.7 including: use of amiodarone at any time during the previous 12 months, use of other antiarrhythmics for the previous 30 days, and use of certain other medications, including certain antidepressants, antihistamines, and macrolides, for the previous 14 days. Any current serious concomitant conditions or renal impairment characterized by serum creatinine levels â‰¥265 mol/L or hepatic impairment characterized by ALT and/or aspartate transferase (AST) levels 3 times the upper limit of the laboratory reference range from the screening lab results. Current clinically relevant changes in the ECG (between Trial 204 day 56 assessment and baseline) such as any atrioventricular (AV) block, prolongation of the QRS complex over 120 msec (in both male and female patients), or the QTcF interval over 450 msec in male patients and 470 msec in female patients. Current clinically relevant cardiovascular disorder such as heart failure, coronary artery disease, uncontrolled or poorly controlled hypertension, arrhythmia, tachyarrhythmia or status after myocardial infarction. Any patients with known or reported significant psychiatric history. For patients with HIV infection, CD4 cell count less than 350/mm3 or on treatment with antiretroviral medication for HIV infection. Karnofsky score under 50% while hospitalized and less than 60% while not hospitalized. Any current diseases or conditions in which the use of nitroimidazoles or nitroimidazole derivates is contraindicated. Evidence of clinically significant metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied). Known or suspected alcohol abuse, that is, abuse sufficient enough to compromise the safety or cooperation of the patient in the opinion of the investigator. Administered an IMP within 1 month prior to Visit 1 other than OPC67683 given as IMP in trial 24207204. Pregnant, breastfeeding, or planning to conceive or father a child within the timeframe described in the informed consent form. Recent use of methadone, benzodiazepines, cocaine, amphetamine/methamphetamine, tetrahydrocannabinol, barbiturates, and opiates as determined by a urine drug screen, unless evidence is provided that the positive drug screen is the result of authorized medications or products prescribed by a physician for a nonabuse related indication. Any disorder that in the judgment of the investigator makes the patient not a good candidate for the trial or may prevent the patient from reliably participating in the entire course of the trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>